ストックスクリーナーアプリを入手
25.85
0.19%
0.05
プレマーケット:
25.93
0.08
+0.31%
前日終値:
$25.80
開ける：
$25.835
24時間の取引高:
51.03M
Relative Volume:
0.76
時価総額：
$146.98B
収益：
$62.79B
当期純損益:
$9.84B
株価収益率:
15.07
EPS:
1.7156
ネットキャッシュフロー:
$10.38B
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
-0.08%
6か月 パフォーマンス:
+4.07%
1年 パフォーマンス:
+1.89%
1日の値動き範囲:
$25.72
$26.04
1週間の範囲:
$25.13
$26.19
52週間の値動き範囲:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.85 | 146.69B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next - ts2.tech
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks - ts2.tech
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - The Motley Fool
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Orion Porfolio Solutions LLC Has $17.19 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025) - ts2.tech
Evergreen Capital Management LLC Purchases 63,611 Shares of Pfizer Inc. $PFE - MarketBeat
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
Pfizer Declares First-Quarter 2026 Dividend - Business Wire
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Treasurer of the State of North Carolina Purchases 520,580 Shares of Pfizer Inc. $PFE - MarketBeat
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
CIBC Asset Management Inc Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Camber Capital Management LP Has $36.36 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. - Britannica
Elevance Health Adds Former Pfizer GC To Its Board - Law360
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield - ts2.tech
Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience - Healthcare Dive
Pfizer plans job cuts in Switzerland to reduce expenses - Yahoo Finance
Down 50%, should you buy the dip on Pfizer? - MSN
Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study - Finviz
Pfizer Inc. $PFE Shares Sold by Schwerin Boyle Capital Management Inc. - MarketBeat
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
Will Obesity Bet and TUKYSA Data Shift Pfizer’s (PFE) Post-COVID Growth Narrative? - simplywall.st
Pfizer Inc. $PFE Shares Sold by Marshall Wace LLP - MarketBeat
Pfizer Inc. $PFE Shares Sold by Becker Capital Management Inc. - MarketBeat
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating - Yahoo Finance
Pfizer Plans Workforce Reduction in Switzerland - marketscreener.com
Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication - Citeline News & Insights
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Pfizer to cut hundreds of jobs in Switzerland by year-end - Investing.com India
Pfizer stock gets Outperform rating from BMO as tucatinib shows promise - Investing.com
Former Pfizer physician challenges RIF, OWBPA disclosures in court - HRD America
Pfizer Plans to Cut 200+ Employees in Switzerland: Wire - AASTOCKS.com
Pfizer is shedding hundreds of jobs in Switzerland (PFE:NYSE) - Seeking Alpha
Pfizer to cut over 200 jobs in Switzerland to reduce costs, Bloomberg News reports - Reuters
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI - MSN
Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI - Finviz
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports - marketscreener.com
Pfizer is cutting hundreds of jobs in Switzerland to lower costsBloomberg News - marketscreener.com
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
2.28%
0.11%
大文字化:
|
ボリューム (24 時間):